Travere says Phase 2 SPARTAN final analysis shows 75% complete proteinuria remission with FILSPARI in IgA nephropathy

By Public Technologies
  • Travere Therapeutics flagged nine new data presentations on FILSPARI for IgA nephropathy, focal segmental glomerulosclerosis at ASN Kidney Week 2026.
  • Results will be presented October 21-25 in Denver, including final Phase 2 SPARTAN findings in newly diagnosed IgA nephropathy.
  • SPARTAN showed many patients reached complete proteinuria remission, with kidney function remaining broadly stable over two years.
  • A Phase 3 DUPLEX post hoc analysis in FSGS without nephrotic syndrome favored FILSPARI over irbesartan on proteinuria remission measures.
  • The same analysis indicated slower kidney function loss, fewer kidney failure events, with a comparable overall safety profile versus irbesartan.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261001650352) on October 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.